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Highly purified human polymorphonuclear (PMN) leucocyte matrix metalloproteinases, collagenase and gelatinase, cleaved human plasma 
Cl-inhibitor at the carboxyl site of Ala43u (P& This led to a concomitant loss of Cl-inhibitor activity. An additional cleavage sjte, at the carboxyl 
site of Seru4’ (PJ, was observed during PMN leucocyte gelatinase-induced inactivation, and .a minor fragment of the plasma Cl -inhibitor was 
generated. 
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1. INTRODUCTION 
Cl-inhibitor inactivates proteinases of the comple- 
ment (Cl r, Cls), fibrinolytic (plasmin), kinin-genera- 
tion (kallikrein) and coagulation (factor XIa, XIEa) sys- 
tem by the formation of equimolar stoichiometric om- 
plexes between inhibitor and target proteinase [1,2]. 
Like in other members of the serine proteinase inhibitor 
(serpin) superfamily, the reactive site of Cl-inhibitor is 
located in an exposed loop near the C-terminus of the 
molecule [3-51. Limited proteolysis of Cl-inhibitor by 
chymotrypsin-like proteinases results in N-terminal mo- 
dification of the molecule without change in inhibitor 
capacity [5--71. Grin proteinases which are not inhibited 
by Cl-inhibitor can cleave within the reactive site loop 
resulting in a loss of inhibitory activity [G,r(,S]. This 
process is accompanied by a conformational rearrange- 
ment and an increase in heat stability. The physiological 
role of Cl -inhibitor has been demonstrated by its invol- 
vement in type I and type II hereditary angiooedema 
[l&12]. It has recently been shown, that human PMN 
leucocytes are able to inactivate Cl-inhibitor by limited 
proteolysis [6]. This is due to proteolytic cleavage of 
PMN leucocyte lastase on the N- and C-terminal part 
of the inhibitor. Since the regulation of the complement 
system is critically dependent on a balance between C 1 r, 
Cls and their inhibitor, proteolytic inactivation of Cl- 
inhibitor by PMN leucocytes may result in complement 
activation. The influence of PMN leucocyte metallopro- 
teinases on the inhibitory activity of Cl-inhibitor is de- 
scribed in this report. The inactivation of Cl-inh.ibitor 
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by PMN leucocyte collagenase and gelatinase isdemon- 
strated, and we discuss tha possible role of PMN leuco- 
cyte metalloproteinases a antagonists of human plas- 
ma C I -inhibitor. 
2. MATERIALS AND METHODS 
2.1, Purification, activation and enzyme assay of PMN lertcocyte ma- 
trix metalloproteinases, collagenase and gelatinase 
PMN leucocyte procollagenase was purified to homogeneity exactly 
as recently published [13]. PMN leucocyte progelatinase was purified 
according to the method described by Wilhelm et al, for the homolo- 
gous enzyme from simian virus 40 transformed lung fibroblasts [ 141. 
It was demonstrated by N-terminal sequence determination that both 
enzyme preparations were homogeneous, showing the N-terminal se- 
quences of PMN leucocyte procollagenase and PMN leucocyte proge- 
latinase. Activation of both proenzymes was achieved by treatment 
with I mM HgClz for 2 h at 37°C. The enzymatic activity of PMN 
leucocyte collagenase and PMN leucocyte gelatinase was determined 
by the degradation of the synthesic octapeptide (DNp-Pro-Gln-Gly- 
Ile-Ala-Gly-Gln-DArg-OH) as described by Masui 1151. 
2.2, Proteolytic inactivation of Cl-inhibitor 
2 mg human Cl-inhibitor were incubated with 5 ,~g of either active 
PMN leucocyte collagcnase or PMN leucocyte gelatinase at 37°C for 
20 h. 
2.3. Purificatiopt of Cl-inhibitor degradation products by reverse-phase 
HPLC 
Fragments from the PMN leucocyte collagenase and PMN leuco- 
cyte gelatinase digests of Cl-inhibitor were separated by reverse-phase 
HPLC on a Bakerbond wide pore &-column (4.9 X 250 mm) at a 
constant flow rate of 0.8 ml/min using a linear gradient from O-80% 
acetonitrile. 
2.4. Sequence detern~ination 
N-terminal sequence determinations of the individual degradation 
products were performed by automated Edman degradation using a 
microsequencer (Model 810, Knauer, Berlin). Pth amino acids were 
separated on an Applied Biosystems Pth-C,,-column (220 x 2.1 mm) 
at a flow rate of 0.24 mllmin as recently published [16]. 
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Fig. 1. Cleavage of Cl-inhibitor by PMN leucocyte collagenase and 
gelatinase. 10% SDS-PAGE unreduced. The protein bands were 
stained with silver. Lane I, molecular mass markers; lane 2. I mg Cl- 
inhibitor incubated with buffee at 37°C for 24 h; lane 3, I mg Cl- 
inhibitor incubated with 5,q active collagenase at 37°C foe 24 h; lane 
4. 1 ma Cl-inhibitor incubated with 5 ug active collaaenase in the 
piesen& of EDTA; lane 5, 1 mg Cl-inhibitor incubated with 5 @g 
active gelatinase at 37°C for 24 h; lane 6.1 mg Cl-inhibitor incubated 
-with 5 pg active gelatinase in the preiencc of EDTA. 
Fig. 2. Reverse-phase HPLC of Cl-inhibitor and Cl-inhibitor degra- 
dation products (A) intact Cl-inhibitor: (E) active collagenase digest 
of Cl-inhibitor; 1, cleavage fragment Ilea N-terminus; (C) active 
gelatinase digest of Cl-inhibitor; I, cleavage fragment Ilea” N-termi- 
nus; 2, cleavage fragment ValU2 N-terminus. 
3. IWSIJLTS AND BISCWSSION 
The rapid proteolytis fragmentation of C 1 -inhibitor 
by highly purified PMN leucocyte collagenase and gela- 
2.5. SDS-PAGE 
The molecular masses of Cl-inhibitor and degradation products 
were analysed by SDS-PAGE as described by Laemmli [l7]. The 
proteins were stained with silver according to the protocol of Heu- 
keshoeven and Dernick [IX]. 
tinase was shown by SDS-PAGE (Fig. 1), reverse-phase 
I-IPLC (Fig. 2) and N-terminal sequence determination 
(Fig. 3). The native Cl-inhibitor was proteolytisally 
cleaved by PMN leucocyte collagenase and gelatinase 
at the Ala439-Ile440 peptide bond. This proteolytic clea- 
vage at the carboxyl site of Ala419 (P,), five residues pre- 
(N&) $.+p-N*. .l"&S-L-Q- “33F-V-E-P-I-L-E-V-6-S”” “4~~S-~-I-S-~-A~~*-T-L_L-V-F~E’- .476p,R-A478(C,,0,.,) 
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t3itfs arientans VOPIOR [6] 
Human skin chymase, human cathepsin G, bovina chymotrypsin [7] 
Buncgarus fasciatus venom [6] 
Human PMN elastase [6] 
Pseudomonas aeruginosa [6] 
Human PMN col.lagenase [this report] 
Human PMN gelatinase (main product) [this report] 
Human PMN gelatinase (minor product) [this report] 
reactive sita [5] 
Fig. 3, Proteolytic modification of human Cl-inhibitor by various proteolytic enzymes as indicated by arrows. 
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Fig. 4. Demonstration of the toss of inhibitory capacity ofCl-inhibitor 
after proteotysis by PMN teucocyte coltagenase and getatinase. (a), 
inactivation of Cl-inhibitor by collagenase after 24 h at 37°C; (A). 
inactivation of Cl-inhibitor by gelatinase after 24 h at 37°C; (0), intact 
Cl-inhibitor after 24 h incubation at 37°C in the presence of buffer. 
The inhibition of human plasmin (IO j&) by Cl-inhibitor (I mg/mt) 
is shown. 
ceding the reactive site, led to the concomitant inactiva- 
tion of the inhibitor (Fig. 4). A further minor fragment 
was generated by proteolytic cleavage of the Ser4”- 
Va1442 peptide bond by PMN leucocyte gelatinase within 
the protein core of the Cl-inhibitor. Inactivation of 
Cl-inhibitor by PMN leucocyte collagenase and gela.ti- 
nase was inhibited by EDTA or l,lO-phenanthroline 
(not shown) indicating metalloproteinase specific clea- 
vage. 
The fragmentation of C l-inhibitor by different prote- 
olytic enzymes of bacterial [9], reptilian [6] and human 
origin [6-81 has been investigated over the last ten years. 
The N-terminal and C-terminal region of the inhibitor 
is sensitive to proteolytic attack. I-Iowever, the loss of 
inhibitory activity is only observed when cleavages 
occur within the reactive site region of the molecule, 
which is located at the C-terminus [S]. This is followed 
by a significant conformational change in the exposed 
reactive site loop of the native inhibitor, which has been 
demonstrated by crystallisation of the inactivated ho- 
mologous serpin @,-PI [19]. Recently, Huber and 
Carrel1 [20] showed that the structural model of q-PI 
can generally act as a template for other members of the 
serpin family. 
Inactivation of Cl-inhibitor by proteinases derived 
from potentially pathogenic organisms or by human 
PMN leucocyte elastase would lead to an imbalance of 
the complement system. This would potentiate patholo- 
gical proteolysis at sites of inflammatory reactions. As 
it was recently shown that PMN leucocyte collagenase 
and g2latinase are regular plasma components [21], we 
investigated the ability of these matrix metalloproteina- 
ses to digest plasma components [22]. Both PMN leuco- 
cyte matrix metalloproteinases, collagenase and gelati- 
nase, can catalytically cleave Cl-inhibitor within the 
reactive site loop and thus may contribute to comple- 
ment activation during inflammation. These enzymes 
could possibly play an important role in the turnover of 
C 1 -inhibitor, since they are easily secreted upon specific 
stimuli and are optimally active at physiological pPI 
[23,24]. PMN leucocyte metalloproteinases may behave 
as the main antagonists of q-PI [22] or Cl-inhibitor. 
Proteolysis of these inhibitors results in the potentiation 
of inflammatory processes, which are regulated by these 
members of the serpin family. IMowever, the physiologi- 
cal significance of Cl-inhibitor inactivation by PMN 
leucocyte matrix metalloproteinases has yet to be deter- 
mined. 
Ackno,vledgei?lerrts: This work was supported by DFG, special re- 
search programme SFB 223 project B2. The authors thank Dr 
Dickneite, Behringwerke, Marburg, Germany for the generous gift of 
Cl-inhibitor. The skilful technical assistance of K. Etzold and S. 
Rottmann is greatfully acknowledged. The authors thank Mrs G. 
Delany for linguistic advice. 
REFERENCES 
[I] Travis, J. and Salvesen, G.S. (1983) Annu. Rev. Biochem. 52, 
655-709. 
[2] Carrel], R.W. and Boswetl, D.R. (1986) in: Proteinase Inhibitors 
(Barrett, A.J. and Salvesen, G.S., eds.) pp. 403-420, Etsevier, 
Amsterdam. 
[33 Carrel], R.W. and Owen, MC. (1985) Nature 317, 730-732. 
[4] Bock, SC., Skriver, K., Nielsen, E., Thorgesen, H.-C., Wiman, 
B., Donaldson, V.H., Eddy. R.L., Marrinan, .I., Radziejewska, 
E., Huber, R., Shows, T.B. and Magnusson, S. (1986) Biochemis- 
try 25,4292-4301. 
[S] Salvesen, G.S., Catanese, J.J., Kress, L.F. and Travis, J. (198s) 
J. Biol. Chem, 260, 2432-2436. 
[G] Pemberton, P.A., Harrison, B.A., Lachmann, P.J. and Carrel], 
R.W. (1989) Biochem. J. 258, 193-198. 
[7] Schoenberger, O.L., Sprows, J.L., Schechter, N.M., Cooperman, 
B.S. and Rubin, H. (1989) FEBS Lett. 259, 165-169. 
[S] Brower, M.S. and Harpet, PC. (1982) J. Biot. Chem. 254.9849- 
9854. 
[9] Bruch, M.. Weiss, V. and Engel, J. (1988) J. Biot. Chem. 263, 
16626-16630. 
[lo] Landermaun, N.S., Webster, M.E., Becker, E.L. and Ratcliffe, 
H.E. (1962) J. Allergy 33, 330-341. 
[I I] Donaldson, V.H. and Evans, R.R. (1963) Am. J. Med. 35,394. 
[t2] Autak, KS., Cicardi, M. and Harrison, R.A. (1990) FEBS Lett. 
266, 13-16. 
[13] Kntiuper, V., Kramer. S., Reinke, H. and Tschesche, H. (1990) 
Eur. J. Biochcm. 189, 295-300. 
[14] Wilhelm, SM., Collier, I.E., Marmer, B.L., Eisen, A.Z., Grant, 
G.A. and Goldberg, G.I. (1989)J. Biol. Chem. 264,17213-17221. 
[15] Masui, Y., Takemoto, T., Sakakibara, S., Hori, H. and Nagai, 
Y. (1977) Biochem. Med. 17, 215-221. 
[16] Reinke, H., Fischer, St., Reimann, F. and Tschesche, H. (1991) 
in: Methods in Protein Sequence Analysis (J&nvalt, H., Hbbg, 
J.-O. and Gustavsson, A.-M., eds.) pp. 55-66, BirkhSluser Verlag, 
Basct. 
[17] Laemmli, U.K. (1970) Nature 227, 680-685. 
[18] Heukeshoven, J. and Dernick, R. (1985) Electrophoresis 6, 103- 
112, 
[19] Locbermann, H., Tokuoka, R., Deisenhoffer, J. and Huber, R. 
(1984) J. Mot, Biot. 177. S3l-55G. 
101 
VO:UEE 230 , IlUtZbCi 1,2 FESSLETTERS September 199 1 
[2O] Huber, R. and Careell, R.W. (1989) Biochemistry Z&8951-8966. 
[21] BerlJmann, U., Michaelis, J., Oberhoff, R.. KnSIuser, V.. Beck- 
ma&, R. and Tschesche, I-I. (1989) J. Clin. Chem. Clin. Biochem. 
1231 Hibbs, MS., Hasty, K.A., Kang, A.H. and Mainardi, C.L. (1984) 
Collarzen Rel. Res. 4. 467477. 
1241 Hast< K.A.. Hibbs. i&S.. Kane. A.H. and Mainardi, C.L. (1986) 
27.151-359. 
_ _ 
J. ISi% Chem. 261,‘5645-5650: 
Kniluper, V., Reinke, I-I. and Tschesche, H. (1990) FEDS Lett. 
263, 355-357. 
WI 
